Clinical Trial Update: Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating zanubrutinib-based combination regimens for newly diagnosed diffuse large B-cell lymphoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Beijing Tongren Hospital | Conditions: Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Status: RECRUITING